Vertex Pharmaceuticals Inc. (VRTX), a commercial-stage global biotechnology company, announced Friday a reimbursement agreement with ...

The European Commission has followed the advice of its human medicines committee and revoked the conditional marketing authorisation for Advanz Pharma's Ocaliva therapy for primary biliary ...

The European Commission revoked the conditional marketing authorisation for Ocaliva (obeticholic acid) earlier this year on the grounds that its benefits no longer outweighed its risks as a ...

CSL Behring's gene therapy Hemgenix four years post-infusion data continue to show sustained efficacy and safety in adults with haemophilia B: King of Prussia, Pennsylvania Monday ...

InflaRx N.V. IFRX shares gained 7.7% on Wednesday following the European Commission's (EC) approval of marketing authorization, under exceptional circumstances, for Gohibic (vilobelimab ...

Data from the study showed that HEMGENIX continues to deliver sustained factor IX activity levels for up to four years post-treatment. The treatment also provides long-term bleed protection, ...

HEMGENIX has been granted conditional marketing authorization by the European Commission (EC) for the European Union and European Economic Area, the UK's Medicines and Healthcare products ...

Vertex Pharmaceuticals (Nasdaq: VRTX) announced today a reimbursement agreement with NHS England for eligible sickle cell disease (SCD) patients to access the CRISPR/Cas9 gene-edited therapy, CASGEVY® ...